New drug delivery nanosystem combining liposomal and dendrimeric technology (liposomal locked-in dendrimers) for cancer therapy.
Liposomal locked-in dendrimers (LLDs), the combination of liposomes and dendrimers in one formulation, represents a relatively new term in the drug carrier technology. LLDs undergone appropriate physicochemical investigation can merge the benefits of liposomal and dendrimeric nanocarriers. In this study generation 1 and 2 hydroxy-terminated dendrimers were synthesized and were then "locked" in liposomes consisting of DOPC/DPPG. The anticancer drug doxorubicin (Dox) was loaded into pure liposomes or LLDs and the final products were subjected to lyophilization. The loading of Dox as well as its in vitro release rate from all systems was determined and the interaction of liposomes with dendrimers was assessed by thermal analysis and fluorescence spectroscopy. The results were very promising in terms of drug encapsulation and release rate, factors that can alter the therapeutic profile of a drug with low therapeutic index such as Dox. Physicochemical methods revealed a strong, generation dependent, interaction between liposomes and dendrimers that probably is the basis for the higher loading and slower drug release from the LLDs comparing to pure liposomes.
Gardikis
Konstantinos
K
National Hellenic Research Foundation (NHRF), Institute of Organic and Pharmaceutical Chemistry, Athens, Greece.
Hatziantoniou
Sophia
S
Bucos
Madalina
M
Fessas
Dimitrios
D
Signorelli
Marco
M
Felekis
Theodoros
T
Zervou
Maria
M
Screttas
Constantinos G
CG
Steele
Barry R
BR
Ionov
Maksim
M
Micha-Screttas
Maria
M
Klajnert
Barbara
B
Bryszewska
Maria
M
Demetzos
Costas
C
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000737:chemistry; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000737:chemistry; D050091:Dendrimers / Q000737:chemistry*; D004055:Differential Thermal Analysis; D004317:Doxorubicin / Q000008:administration & dosage / Q000737:chemistry; D004337:Drug Carriers; D004339:Drug Compounding; D016503:Drug Delivery Systems; D005612:Freeze Drying; D007202:Indicators and Reagents; D008081:Liposomes / Q000737:chemistry*; D008560:Membrane Fluidity; D009369:Neoplasms / Q000188:drug therapy*; D010713:Phosphatidylcholines; D010715:Phosphatidylglycerols; D012995:Solubility; D013050:Spectrometry, Fluorescence
D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D050091:Dendrimers; D004337:Drug Carriers; D007202:Indicators and Reagents; D008081:Liposomes; D010713:Phosphatidylcholines; D010715:Phosphatidylglycerols; D004317:Doxorubicin; C017251:1,2-oleoylphosphatidylcholine; C030345:1,2-dipalmitoylphosphatidylglycerol